QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders. Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma’s product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales. The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.
QRxPharma’s lead compound, MoxDuo® IR (Q8003IR), is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. Study results consistently demonstrate MoxDuo IR’s greater overall tolerability, achieving as good or better pain relief with substantially fewer incidences of moderate to severe side effects. The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics.
News
QRxPharma Announces Strategic Partnership with Actavis 
21 December 2011
Change of Director's Interest Notice - John Holaday
22 November 2011
Appendix 3B - Option Issue
18 November 2011
Results of 2011 Annual General Meeting
16 November 2011
Chairman's and Managing Director's Addresses to Shareholders 2011 Annual General Meeting
16 November 2011
PDUFA Target Date for FDA Action on MoxDuo IR NDA Granted
8 November 2011
Appendix 4C - Quarter Ended 30 September 2011
27 October 2011
2011 Notice of Annual General Meeting and Proxy Form
14 October 2011
Appendix 3B Exercise of Stock Options
28 September 2011
Annual Report to Shareholders – 2011
27 September 2011
Change of Director's Interest Notice – Peter Farrell
1 September 2011
Change of Director's Interest Notice – Gary Pace
1 September 2011
Change of Director's Interest Notice – Michael Quinn
1 September 2011
Change of Director's Interest Notice – Peter Campbell
1 September 2011
Non-renounceable Rights Issue Despatch of Holding Statements
30 August 2011
Appendix 3B - Rights Issue
30 August 2011
QRxPharma Completes NDA Submission for MoxDuo® IR
25 August 2011
Non-renounceable Rights Issue Notice of under subscriptions
25 August 2011
Appendix 4E – Preliminary Financial Report 30 June 2011
18 August 2011
Initiation of NDA Filing Caps Off Another Successful Year for MoxDuo® Pain Therapy Development
18 August 2011
Corporate Update and Rights Issue closing 22 August 2011
15 August 2011
QRxPharma CEO discusses Recent Milestones and Rights Issue
on Boardroom Radio
[Click here to listen to the broadcast]
10 August 2011
Notice of Despatch of Rights Issue Documents to Shareholders
08 August 2011
Rights Issue - Notice to Ineligible Shareholders
08 August 2011
Rights Issue - Letter to U.S. Eligible Shareholders
08 August 2011
Appendix 3B - Exercise of Stock Options
02 August 2011
Appendix 4C - Quarter Ended 30 June 2011
28 July 2011
Non-Renounceable Rights Issue - Letter to Shareholders
22 July 2011
Non-Renounceable Rights Issue - Letter to Option Holders
22 July 2011
QRxPharma Rights Issue - Entitlement and Acceptance Form
22 July 2011
QRxPharma Rights Issue Booklet
22 July 2011
Notification Section 708AA(2)(f) Corporations Act
22 July 2011
Appendix 3B - Placement and Rights Issue
22 July 2011
Investor Update and Capital Raising
20 July 2011
Trading Halt
20 July 2011
QRxPharma Announces NDA Filing for MoxDuo® IR
18 July 2011
Additional Data on MoxDuo® IR Comparative Safety Study
29 June 2011
QRxPharma Corporate Overview Presentation
20 June 2011
QRxPharma CEO discusses Comparative Safety Study on Boardroom Radio
15 June 2011
QRxPharma Completes Comparative Safety Study
14 June 2011
Appendix 4C: Quarterly Report 31 March 2011
28 April 2011
QRxPharma Completes Patient Enrolment of MoxDuo®IR Phase 3 Comparative Safety Study
27 April 2011
USPTO Issues QRxPharma a New Patent for MoxDuo® IR
14 April 2011
QRxPharma on Track to File New Drug Application Mid-Year
28 March 2011
QRxPharma Corporate Overview Presentation
21 February 2011
Half Yearly Report and Accounts – 31 December 2010
21 February 2011
Successful Completion Third Pivotal MoxDuo® IR Phase 3
21 February 2011
Quarterly Operating Update 31 December 2010
27 January 2011
QRxPharma Initiates Phase 3 Comparative Safety Study of MoxDuo®IR
24 January 2011
Appendix 3B - Option Issue
6 January 2011
QRxPharma Securities Trading Policy
31 December 2010
Enrolment of Pivotal MoxDuo IR Phase 3 Study Completed
6 December 2010
$5.8 Million SPP Completes Capital Raising of $19.8 million
19 November 2010
Appendix 3B - Option Issue to Directors
9 November 2010
Notification Section 708A(5)(e) Corporations Act 2001
9 November 2010
Appendix 3B - 2nd Tranche of Placement Issue
9 November 2010
Amended Company Constitution
8 November 2010
Results of 2010 Annual General Meeting
8 November 2010
Chairman's and Managing Directors' Addresses to Shareholders 2010 Annual General Meeting
8 November 2010
Additional U.S. Therapeutic Discovery Project Grant Awarded
8 November 2010
QRxPharma Awarded Grants Totalling US$489,000 for Two MoxDuo® Pain Management Product Candidates
4 November 2010
Appendix 4C Quarterly Report
27 October 2010
Share Purchase Plan opens 18 October 2010
15 October 2010
Annual Report 2010
8 October 2010
2010 Notice of Annual General Meeting and Proxy
6 October 2010
QRxPharma Limited Announces A$14 Million Placement together with
a Share Purchase Plan
1 October 2010
Trading Halt Announcement
29 September 2010
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for
MoxDuo® IR
1 September 2010
Another successful year for MoxDuo® Pain Therapy Development
26 August 2010
Appendix 4E – Preliminary Financial Report FY 2010
26 August 2010
Frost & Sullivan recognises QRxPharma's MoxDuo® IR for innovation in pain therapy
18 August 2010 [Click here to read the Frost & Sullivan Report]
QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for
MoxDuo® IV Pain Therapy
9 August 2010
Positive Scientific Advice Meetings in Europe MoxDuo® IR
26 July 2010
Appendix 4C Quarterly Report
30 June 2010
Webcast Link: QRxPharma Presentation at Noble Financial's Equity Conference
11AM EDT, 7 June 2010 
1 June 2010
ASX Spotlight: John Holaday, Managing Director and CEO, QRxPharma 
24 May 2010
Third Quarter Operating Update
27 April 2010
QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo® IR in Patients with Post-Surgical Pain
14 April 2010
QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo®IV
23 February 2010
QRxPharma Limited ASX – Half-Year Report 31 December 2009
17 February 2010
QRxPharma Initiates Second Pivotal Phase 3 Study of
MoxDuo™ IR Dual-Opioid™ for NDA Submission
10 February 2010
Second Quarter Operating Update
27 January 2010
Change of Director's Interest Notice - Gary Pace
23 December 2009
Change of Director's Interest Notice - John Holaday
23 December 2009
Change of Director's Interest Notice - Michael Quinn
23 December 2009
Change of Director's Interest Notice - Peter Farrell
23 December 2009
Change of Director's Interest Notice - Peter Campbell
23 December 2009
Appendix 3B - Rights Issue
23 December 2009
Change in substantial holding
23 December 2009
Rights Issue - Notice of Despatch of Shareholder Statements
21 December 2009
Notice of Subscriptions under Rights Issue
18 December 2009
Appendix 3B Rights Issue
18 December 2009
Appendix 3Y Change of Director’s Interest Notice
18 December 2009
Appendix 3Y Change of Director’s Interest Notice
11 December 2009
Appendix 3Y Change of Director’s Interest Notice
10 December 2009
Appendix 3Y Change of Director’s Interest Notice
10 December 2009
Corporate Update and Rights Issue closing 15 December 2009
10 December 2009
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo™IR For Moderate to Severe Acute Pain
30 November 2009
Notice of Despatch of Rights Issue Documents to Shareholders
30 November 2009
Rights Issue - Notice to Ineligible Shareholders
30 November 2009
Rights Issue - Letter to U.S. Eligible Shareholders
30 November 2009
Appendix 3Y Change of Director’s Interest Notice
23 November 2009
Appendix 3B New Issue Announcement
23 November 2009
Appendix 3B New Issue Announcement
19 November 2009
QRxPharma Limited Announces A $21.6 Million Fully Underwritten Capital Raising
16 November 2009
QRxPharma Renounceable Rights Issue Booklet
16 November 2009
Renounceable Rights Issue - Entitlement and Acceptance Form
16 November 2009
Appendix 3B - Placement and Rights Issue
16 November 2009
Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)
16 November 2009
Renounceable Rights Issue - Letter to Option holders
16 November 2009
Renounceable Rights Issue - Letter to Shareholders
16 November 2009
Reinstate ment to Official Quotation
16 November 2009
Chairman's and Managing Directors' Addresses to Shareholders
16 November 2009
Results of 2009 Annual General Meeting
16 November 2009
QRxPharma Corporate Presentation
13 November 2009
Voluntary Suspension from Trading
13 November 2009
Australian Securities Exchange Trading Halt
11 November 2009
First Quarter Operating Update
26 October 2009
QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
20 October 2009
QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo™CR
12 October 2009
2009 Annual General Meeting
9 October 2009
Annual Report 2009
28 September 2009
QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
24 September 2009
M oxDuo™ IR Demonstrates Fewer Side Effects than Percocet®
25 August 2009
Appendix 4E – Preliminary Financial Report FY 2009
21 August 2009
Fourth Quarter Operating Update
28 July 2009
Third Quarter Operating Update
27 April 2009
QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy
20 April 2009
QRxPharma Limited ASX Half-Year Report – 31 December 2008
23 February 2009
QRxPharma Initiates Second Comparative Study for MoxDuo™ IR DualOpioid™ Pain Therapy
19 February 2009
Secon d Quarter Operating Update
28 January 2009
QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy
16 December 2008
Notice of Change of Interests of Initial Substantial Shareholder
10 December 2008
Notice of Initial Substantial Shareholder
9 December 2008
2008 Annual General Meeting – Chairman and Managing Director
Addresses
4 November 2008
Results of 2008 Annual General Meeting
4 November 2008
Notice of Annual General Meeting
26 September 2008
Annual Report 2008
26 September 2008
QRxPharma On Track with Successful Completion During the Year of Initial Phase 3 Trials for its Lead Dual-Opioid® Q8003IR
21 August 2008
Fourth Quarter Operating Update
21 August 2008
Change of Director’s Interest Notice
12 August 2008
Appendix 4C: Quarterly Report for Entities Admitted on the Basis of Commitments
30 July 2008
Change of Director’s Interest Notice
3 July 2008
QRxPha rma Begins Trading on the International OTCQX
1 July 2008
FY0 8 Appendix 4E — ASX Preliminary Final Report
30 June 2008
Change of Director's Interest Notice
1 July 2008
Change of Director's Interest Notice
30 June 2008
Change of Director's Interest Notice
27 June 2008
Corporate Presentation
June 2008
QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy
22 May 2008
Release of Shares from Restriction and Escrow
19 May 2008
QR xPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
5 May 2008
Third Quarter Operating Update
28 April 2008
QRxPharma Limited ASX – Half-Year Report 31 December
2007
26 February 2008
Resignation of Company Secretary
15 February 2008
Second Quarter Operating Update
29 January 2008
QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy
13 December 2007
Change of Registered Office and Principal Administrative Office
30 November 2007
Q RxPharma Enrolls First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy
26 November 2007
2010 Notice of Annual General Meeting and Proxy
2 November 2007
2007 Annual General Meeting - Chairman & Managing Director Addresses
2 November 2007
First Quarter Operating Update
22 October 2007
Inve stor Update
22 October 2007
Annual report 2007
27 September 2007
Notice of Annual General Meeting
27 September 2007
FY07 Results Corporate Presentation
Preliminary Final Report
15 August 2007
FY07 Appendix 4E - Preliminary Final Report
15 August 2007
Appendix 4C Quarterly Report
27 July 2007